|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||18.95 - 19.26|
|52 Week Range||9.13 - 23.50|
|Beta (5Y Monthly)||0.73|
|PE Ratio (TTM)||20.90|
|Forward Dividend & Yield||0.82 (4.46%)|
|Ex-Dividend Date||Oct 17, 2019|
|1y Target Est||24.39|
Smiths Detection today announces that it has partnered with Attomarker Ltd, a multiplex blood-testing technology company spun out of the University of Exeter, to help produce a robust and accurate COVID-19 antibody-testing device that could represent an evolution in rapid and precise COVID-19 antibody testing. The Medicines and Healthcare Products Regulatory Agency (MHRA) has already approved Attomarker’s Triple Antibody Test for NHS use in the UK.
Moody's Investors Service has today affirmed the long-term issuer rating of Smiths Group plc. The outlook remains stable. The affirmation reflects Moody's expectation that the company should be in a position to maintain metrics in line with the expectation for the rating, although its divisions John Crane, Detection and Flex-Tek are likely to come under some pressure from challenges in certain end markets over the next 12 months in particular aerospace and oil & gas. Moody's also continues to note that there is some uncertainty and potential pressure on the rating from the planned Medical division demerger.
Smiths Detection, a leading detection and security company, has launched iCMORE detection algorithms for lithium batteries and dangerous goods for use by its HI-SCAN 10080 XCT scanner, becoming its first explosive-detection system (EDS) to offer these options. The algorithms enhance the scanner’s detection capabilities by helping identify lithium batteries, flammable liquids and solids, and compressed and liquefied gasses, which can pose a risk should they ignite or explode.
Smiths Detection, a leading threat-detection and security-technology company, will supply hold-baggage screening equipment for Kuwait’s new International Airport Terminal 2, which is currently under construction. The contract includes the installation of HI-SCAN 10080 XCT units for screening hold baggage.
Smiths Detection, a global leader in detection and screening technologies, today announces that it has entered into an agreement to acquire PathSensors, a leading bio-technology solutions and environmental-testing company based in Baltimore, MD. The acquisition expands Smiths Detection’s sensing capabilities across the CBRNE (chemical, biological, radiological, nuclear and explosive) spectrum to respond quickly to emerging threats.
Smiths Detection launches Ultraviolet Light Upgrade Kits for checkpoints capable of killing 99.9% of microorganisms on baggage trays
Those holding Smiths Group (LON:SMIN) shares must be pleased that the share price has rebounded 31% in the last thirty...
(Bloomberg) -- When Britain’s government issued an urgent call to industry for thousands of hospital ventilators, more than 5,000 companies offered to help. Coronavirus infections are expected to peak next week and there’s little to show for their effort.Significant deliveries from the firms are still weeks away, and the embattled National Health Service has resorted to foreign imports and loans from the armed forces and the private sector to double its ventilator count to around 10,000. While the national lockdown appears to be slowing the spread of Covid-19, the NHS may need as many as 8,000 more of the devices, according to Health Secretary Matt Hancock.The government is under intense pressure to solve Britain’s shortage of the machines that are vital for treating critically ill patients. It already spurned an offer to join a European Union program for procuring ventilators, initially stating it was no longer a member of the bloc and could source them locally, before backtracking and saying it had missed the email inviting participation. EU leaders are struggling to coordinate a response to the virus; last night they were unable to agree on a 500 billion-euro ($543 billion) stimulus package.It’s not that U.K. Plc can’t do the job: The machines are seen as relatively straightforward to make and much of industry has been sitting on its hands since the economy tanked. The problem is that vacuum cleaner maker Dyson Ltd., engineering contractor Babcock International Group Plc and other newcomers to the business need their designs to be fully tested and approved.It can take months for the U.K. Medicines & Healthcare Products Regulatory Agency to sign off on sensitive medical machinery. The process can be expedited, but still takes valuable time to ensure patients’ safety.“It’s a race against the clock,” said Derek Hill, a professor specializing in medical devices at University College London. The regulator is “literally working all hours making this happen fast.”For now, the supply of ventilators from British manufacturers is tiny. The NHS expects to receive 30 locally-made machines this week, compared to 300 sourced from China over the weekend.Department of Health and Social Care officials say they are confident there will be enough ventilators to meet demand, given the steps being taken to increase the number available, and as long as people continue to stay at home to reduce the spread of the virus.Pistons, TurbochargersIn the short run, the greatest hope lies with consortium Ventilator Challenge UK, which includes Meggitt Plc, Airbus SE, GKN Ltd, McLaren Automotive Ltd and Rolls-Royce Holdings Plc. They plan to churn out 1,500 ventilators a week using designs from Penlon Ltd. and Smiths Group Plc, two medical device makers that can currently only make about 50 to 60 of the machines per week on their own. The group already has an approved ventilator from Smiths. But it’s still closing in on final approval for the other, and its factories and supply chains are in need of re-calibrating, so large deliveries are unlikely before the end of April.A breathing aid developed by engineers from the Mercedes Formula One team and University College London has been approved for use. It’s being manufactured at a rate of as many as 1,000 a day using machines that would normally produce racing car pistons and turbochargers. It’s not as sophisticated as a ventilator, but it can help reduce the need for those devices.Companies such as Babcock -- which has a government contract to make 10,000 of its Zephyr Plus ventilators -- face a longer wait for approval. They may end up being useful in a potential second or third wave of infection.Prime Minister Boris Johnson, who is in hospital with the disease, set a challenge last month to source 30,000 ventilators.The government now says fewer will be needed because lockdown measures have slowed the virus’s spread. The NHS has 2,000 extra ventilators on standby, with 1,500 more due to arrive by the end of the week, Hancock said on Sunday.(Updates with news on EU fiscal stimulus in third paragraph; adds context)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
British technology firm Smiths Group said it was making one of its ventilators available for other manufacturers to produce, part of a coordinated attempt to tackle a shortage of life-saving equipment as coronavirus spreads. The group's Smiths Medical unit was providing intellectual property and advice to other companies to make its PARAPAC Plus lightweight ventilators, and it was ramping up its own production at its site in Luton, just north of London. Smiths said it was also talking to contract manufacturers to add production capacity in the United States and elsewhere.
To the annoyance of some shareholders, Smiths Group (LON:SMIN) shares are down a considerable 49% in the last month...
Dividend paying stocks like Smiths Group plc (LON:SMIN) tend to be popular with investors, and for good reason - some...
This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios...
Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Smiths Group plc and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers. This publication does not announce a credit rating action and is not an indication of whether or not a credit rating action is likely in the near future.
Investing.com -- Here is a rundown of the regulatory news releases from the London Stock Exchange on Wednesday, 13th November. Please refresh for updates.
Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Smiths Group...
Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the...
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...